M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
TL;DR: An overview on mAbs currently approved for the treatment of multiple myeloma and promising compounds under investigation is presented.
Journal ArticleDOI
Melphalan hydrochloride for the treatment of multiple myeloma.
Fabrizio Esma,Marco Salvini,Rossella Troia,Mario Boccadoro,Alessandra Larocca,Chiara Pautasso +5 more
TL;DR: Melphalan remains crucial in therapy of multiple myeloma because of its good manageability, safety profile, efficacy, and economic sustainability, which make it pivotal also for new regimens in combination with novel agents.
Journal ArticleDOI
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
Simone Ferrero,Daniela Capello,Mirija Svaldi,Michela Boi,Daniela Gatti,Daniela Drandi,Davide Rossi,Sara Barbiero,Barbara Mantoan,Elisabetta Mantella,Manuela Zanni,Paola Ghione,Alessandra Larocca,Roberto Passera,Francesco Bertoni,Valter Gattei,Francesco Forconi,Luca Laurenti,Giovanni Del Poeta,Roberto Marasca,Sergio Cortelazzo,Gianluca Gaidano,Antonio Palumbo,Mario Boccadoro,Marco Ladetto +24 more
TL;DR: Analysis of multiple myeloma immunoglobulin repertoire does not support a pathogenetic role for antigen selection in this tumor.
Journal ArticleDOI
Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients
Antonio Palumbo,Sara Bringhen,Davide Rossi,Maide Cavalli,Roberto Ria,Silvia Gentilini,Francesca Patriarca,Chiara Nozzoli,Anna Levi,Tommasina Guglielmelli,Giulia Benevolo,Donatella Vincelli,Luca Baldini,Fortunato Morabito,Mariella Grasso,Roberto Marasca,Manuela Rizzo,Chiara Pautasso,Antonietta Falcone,Daniela Gottardi,Vittorio Montefusco,Caterina Musolino,Clotilde Cangialosi,Giovanna Mansueto,Anna Marina Liberati,Valeria Magarotto,Paola Omedè,Pellegrino Musto,Maria Teresa Petrucci,Mario Boccadoro +29 more
TL;DR: VMPT-VT significantly prolonged OS compared with VMP, especially in patients younger than 75 years and in patients achieving CR after induction, and it should be considered a new standard care.
Journal ArticleDOI
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
Marco Ladetto,Simone Ferrero,Daniela Drandi,Moreno Festuccia,Francesca Patriarca,Nicola Mordini,Silvia Cena,R Benedetto,Guglielmo Guarona,Federica Ferrando,Lucia Brunello,Paola Ghione,V Boccasavia,R Fanin,Paola Omedè,Luisa Giaccone,Antonio Palumbo,Roberto Passera,Mario Boccadoro,Benedetto Bruno +19 more
TL;DR: Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma shows promising results.